Market Newsdesk

American Healthcare REIT Announces Pricing of Public Offering of Common Stock

IRVINE, Calif.–(BUSINESS WIRE)–
American Healthcare REIT, Inc. (NYSE: AHR; the “Company”) announced today the pricing of an underwritten public offering of 14,000,000 shares of its common stock, all of which are being offered in connection with the forward sale agreement described below. The aggregate gross proceeds to the Company from the offering, before deducting estimated offering expenses, are expected to be approximately $705.6 million. The offering is expected to close May 22, 2026, subject to customary closing conditions.

BofA Securities is acting as the underwriter for the offering.

In connection with the offering, the Company entered into a forward sale agreement with BofA Securities (or an affiliate thereof) (the “forward purchaser”), with respect to 14,000,000 shares of the Company’s common stock.

The underwriter has been granted a 30-day option, exercisable in whole or in part from time to time, to purchase up to an additional 2,100,000 shares of the Company’s common stock. If the option to purchase additional shares of the Company’s common stock is exercised, the Company expects to enter into an additional forward sale agreement with the forward purchaser in respect of the number of shares of the Company’s common stock that are subject to exercise of the option to purchase additional shares.

In connection with the forward sale agreement and any additional forward sale agreement, the forward purchaser (or its affiliate) is expected to borrow from third parties and sell to the underwriter an aggregate of 14,000,000 shares of the Company’s common stock (or an aggregate of 16,100,000 shares of the Company’s common stock if the underwriter’s option to purchase additional shares is exercised in full). However, the forward purchaser (or its affiliate) is not required to borrow and sell such shares if, after using commercially reasonable efforts, the forward purchaser (or its affiliate) is unable to borrow such shares, or if borrowing costs exceed a specified threshold or if certain specified conditions have not been satisfied. If the forward purchaser (or its affiliate) does not deliver and sell all of the shares of the Company’s common stock to be sold by it to the underwriter, the Company will issue and sell to the underwriter a number of shares of its common stock equal to the number of shares that the forward purchaser (or its affiliate) did not deliver and sell, and the number of shares underlying the relevant forward sale agreement or such additional forward sale agreement will be decreased by the number of shares that the Company issues and sells.

Pursuant to the terms of the forward sale agreement and any additional forward sale agreement, and subject to its right to elect cash or net share settlement, the Company intends to issue and sell, upon physical settlement of the forward sale agreement and any additional forward sale agreement, an aggregate of 14,000,000 shares of common stock (or an aggregate of up to 16,100,000 shares of common stock if the underwriter’s option to purchase additional shares is exercised in full) to the forward purchaser. The Company expects to physically settle the forward sale agreement and any additional forward sale agreement within approximately 24 months from the date of the prospectus supplement relating to the offering. Upon physical settlement of the forward sale agreement, the Company is entitled to receive cash proceeds per share equal to the applicable forward sale price, and will be subject to certain adjustments as provided in the forward sale agreement.

The underwriter proposes to offer the shares of common stock from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices, subject to receipt and acceptance by it and subject to its right to reject any order in whole or in part.

The Company will not receive any proceeds from the sale of shares of its common stock by the forward purchaser (or an affiliate thereof). The Company expects to contribute any net proceeds from the settlement of the forward sale agreement to the Company’s operating partnership in exchange for OP Units, and the Company expects the operating partnership to use such net proceeds for general corporate purposes, including potential future investments.

All of the shares of common stock are being offered pursuant to the Company’s effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”). A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, a copy of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: [email protected]; or by visiting the EDGAR database on the SEC’s web site at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About American Healthcare REIT, Inc.

American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, and in the United Kingdom and the Isle of Man.

Forward-Looking Statements

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “can,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “possible,” “initiatives,” “focus,” “seek,” “objective,” “goal,” “strategy,” “plan,” “potential,” “potentially,” “preparing,” “projected,” “future,” “long-term,” “once,” “should,” “could,” “would,” “might,” “uncertainty” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Any such forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which the Company operates, and beliefs of, and assumptions made by, the Company’s management and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied therein, including, without limitation, risks disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any obligation to update or revise any forward-looking statements contained in this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520224502/en/

Alan Peterson

VP, Investor Relations & Finance

(949) 270-9200

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Finance REIT Professional Services Practice Management Managed Care Health General Health

MEDIA:

Logo

Oceanhawk Acquisition Corp. Announces Pricing of Upsized $160,000,000 Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Oceanhawk Acquisition Corp. (Nasdaq: OHAC) (the “Company”) today announced the pricing of its upsized initial public offering of 16,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Stock Market (“Nasdaq”) and trade under the ticker symbol “OHACU” beginning May 21, 2026. Each unit consists of one Class A ordinary share and one right to receive one-fourth of one Class A ordinary share upon the consummation of an initial business combination.

Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols “OHAC” and “OHACR”, respectively.

The underwriter has been granted a 45-day option to purchase up to an additional 2,400,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on May 22, 2026, subject to customary closing conditions.

The Company, which is led by Chief Executive Officer Ernest Miller, is a blank check company incorporated as a Cayman Islands exempted company whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. Mr. Miller has over 25 years of experience in the commodity‑driven energy sector, with a background in financial management, strategic planning and the positioning of complex, capital‑intensive companies. While the Company may pursue an initial business combination in any industry or sector, it intends to focus on high‑potential businesses globally, leveraging the experience and network of the Oceanhawk platform.

The Benchmark Company, LLC is acting as the sole book-running manager for the offering.

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission (“SEC”), and was declared effective on May 20, 2026. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from The Benchmark Company, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, by email at [email protected], or from the SEC website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Oceanhawk Acquisition Corp.

Oceanhawk Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. Oceanhawk Acquisition Corp. is sponsored by Oceanhawk Acquisition I Sponsor LLC, an affiliate of Oceanhawk, a private investment firm, and intends to leverage Oceanhawk’s experience, network and operating platform in identifying and evaluating potential business combination opportunities.

Forward-Looking Statements

This press release includes forward-looking statements. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including the successful consummation of the Company’s initial public offering, are subject to risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and preliminary prospectus for the offering filed with the SEC, any of which could cause actual results to differ from such forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520794633/en/

Ernest B. Miller

Chief Executive Officer

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Business Finance

MEDIA:

Posted on May 20, 2026 9:03 pm

Cohen & Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy

PR Newswire

NEW YORK, May 20, 2026 /PRNewswire/ — Cohen & Steers, Inc. (NYSE: CNS), today announced it is partnering with J.P. Morgan to provide access to the Cohen & Steers SICAV Short Duration Hybrid Credit & Income Fund for investors outside the United States across J.P. Morgan’s global wealth management platform, offering their clients a cash alternative.

The Cohen & Steers SICAV Short Duration Hybrid Credit & Income Fund seeks to provide investors with high current income as the primary objective, and capital preservation as a secondary objective, through investments in global hybrid credit securities, while targeting a weighted average duration of less than three years. Hybrid credit securities offer investment opportunities with higher yields than similarly rated bonds. By targeting low duration securities, the Fund seeks to reduce portfolio interest-rate sensitivity.

Elaine Zaharis
‑
Nikas, Head of Fixed Income & Preferred Securities at Cohen & Steers, said:
“Hybrid credit continues to stand out as a compelling source of high
‑
quality income, particularly for investors seeking resilience in a shifting rate environment. Our short
‑
duration approach is designed to help investors harvest attractive yields while mitigating interest
‑
rate sensitivity, and we are excited to bring this capability to more investors through our partnership with J.P. Morgan.”

David Conway, Head of International Wholesale Distribution at Cohen & Steers, said:

“We are pleased to partner with one of the world’s largest and most highly regarded banks and asset management organizations. As pioneers in hybrid credit strategies, today’s announcement highlights the broader industry shift towards greater diversification within fixed income portfolio allocations.”

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

This is a marketing communication. Please refer to the

prospectus

of the Cohen & Steers SICAV and to the relevant

KIID

/

KID

before making any final investment decisions. These documents are available free of charge on the Cohen & Steers website.

About Cohen & Steers SICAV Funds. The Funds are sub-funds of Cohen & Steers SICAV, a Luxembourg-domiciled undertaking for collective investment in transferrable securities (UCITS). Shares of the Funds are only offered pursuant to the current prospectus and the sales of shares of the Funds may be restricted in certain jurisdictions. The Funds have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or under any applicable securities laws of any state or other jurisdiction of the United States. The Funds are not registered under the U.S. Investment Company Act of 1940. Shares may not be offered or sold, directly or indirectly in the United States or to U.S. persons, as more fully described in the Funds’ prospectus. This document does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States. Please see the prospectus for additional information including important risk considerations, potential loss of capital, and details about fees and expenses. Past performance is no guarantee of future results.

Potential Risks: Investment risk including possible loss of entire amount invested. Increased credit risk due to subordination to all other types of corporate debt. Default risk because the issuer experiences a decline in its financial status. Contingent Convertible Securities (“CoCos”) are typically subject to greater levels of credit and liquidity risk. Call risk can cause the sub-fund to invest in lower yielding securities. Increases in interest rates may cause process to fall. Foreign security risk due to currency fluctuations, lower liquidity, political and economic uncertainties and differences in accounting standards. Subject to liquidity risk.

Website: https://www.cohenandsteers.com
Symbol: NYSE: CNS

View original content:https://www.prnewswire.com/news-releases/cohen–steers-announces-strategic-partnership-with-jp-morgan-to-expand-access-to-short-duration-hybrid-credit-sicav-strategy-302778216.html

SOURCE Cohen & Steers, Inc.

Posted on May 20, 2026 8:24 pm

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.

Jefferies, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the offering. Raymond James is acting as lead manager. The offering is expected to close on or about May 22, 2026, subject to customary closing conditions.

The shares of common stock are being offered by Relay Therapeutics pursuant to an automatically effective shelf registration statement on Form S-3ASR (File No. 333-281308) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on August 6, 2024. The offering is being made solely by means of a written prospectus and a prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on May 19, 2026. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected]; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at [email protected]; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Relay Therapeutics

Relay Therapeutics is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PIK3CA-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the closing of Relay Therapeutics’ anticipated public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release, such as the intended offering terms, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Relay Therapeutics’ other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the public offering filed with the SEC. Any forward-looking statements contained in this press release represent Relay Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contact

:


Mitch Maisel
[email protected]

Media:

Dan Budwick
1AB
973-271-6085
[email protected] 

Posted on May 20, 2026 8:03 pm

ISG Announces 2026 ISG Paragon Awards™ ANZ Winners

ISG Announces 2026 ISG Paragon Awards™ ANZ Winners

Program spotlights innovative partnerships that leverage AI, digital technology and new operating models to drive business success

SYDNEY–(BUSINESS WIRE)–
Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has announced the winners of the 2026 ISG Paragon Awards™ ANZ, which recognize innovative sourcing partnerships that help enterprises leverage technology to make a significant and lasting impact on their businesses.

A total of 43 nominations were submitted for the ANZ program, which started in 2010 and is now in its sixteenth year. Winners were selected by an independent judge and announced at a gala awards dinner on Thursday, May 14, 2026, at the Sofitel Sydney Darling Harbour.

The winners of the 2026 ANZ awards are:

AI Pacesetter:Substantial business impact through the adoption of AI

Winner:PWC Australia with AUSREO

Community and Social Excellence: Exceptional delivery and innovation by a technology or service provider creating meaningful impact for Australian or New Zealand communities and citizens

Winner: WNS Vuram, part of Capgemini, with Horizon Power

Excellence: Outstanding delivery by a service provider

Winner: Accenture with Commonwealth Bank of Australia

Innovation: Imagination and entrepreneurial spirit in helping organizations future-proof their businesses and better serve clients

Winner: Avanade Australia Pty. Ltd. with Seqwater

Transformation: The successful transformation of an organization or key business function

Winner: NRI with DroneShield

Partnership of the Year: Partnerships that demonstrate seamless collaboration, leverage each other’s strengths and adapt together to achieve shared objectives

Winner: Probe Group with the Department of Transport and Planning

“Enterprises seek partners that can help them execute on a long-term vision and adapt to new technology and business needs,” said Michael Gale, partner and regional leader, ISG ANZ and Asia Pacific. “Congratulations to the winners of the 2026 ISG Paragon Awards for ANZ, whose commitment to delivering meaningful business results is reflected in each of their winning partnerships.”

The ISG Paragon Awards is a global program recognizing outstanding collaborations between enterprises and providers in all regions. Full details of the ANZ awards are available here.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520634395/en/

Press Contacts:

Laura Hupprich, ISG

+1 203-517-3132

[email protected]

Erik Arvidson, Matter Communications for ISG

+1 978-518-4542

[email protected]

KEYWORDS: Australia/Oceania Australia

INDUSTRY KEYWORDS: Data Management Apps/Applications Technology Other Technology Software Networks Artificial Intelligence

MEDIA:

Logo